test

Clinical Trials

Lung Cancer

10
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), (S1206/NCI Study Number 8811)
Principal Investigator: Roy Decker
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Sarah Goldberg
A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Cisplatin in Subjects with Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)
Disease/Condition: Lung
Principal Investigator: Anne Chiang
A Phase I Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Scott Gettinger
A Phase I, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Disease/Condition: Breast - Female | Kaposi's sarcoma | Lung | Melanoma, skin | Ovary | Soft Tissue
Principal Investigator: Joseph Kim
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Disease/Condition: Lung
Principal Investigator: Sarah Goldberg
A Phase I/II Trial of Evaluating the Combination of MK-3475 and Stereotactic Body Radiotherapy in Patients with Metastatic Melanoma or NSCLC
Disease/Condition: Lung | Melanoma, skin
Principal Investigator: Roy Decker
A Phase I/II, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lung | Pancreas | Stomach
Principal Investigator: Joseph Paul Eder
A Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Scott Gettinger
A Phase II Study of MK-3475 in Patients with Metastatic Melanoma or Non-Small Cell Lung Cancer with Untreated Brain Metastases
Disease/Condition: Lung | Melanoma, skin
Principal Investigator: Harriet Kluger
A Phase II, Multicenter, Single-arm Study of Oral AP26113 in Patients with ALK-positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated with Crizotinib
Disease/Condition: Lung
Principal Investigator: Scott Gettinger
A Phase II,Non-comparative,Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen
Disease/Condition: Lung
Principal Investigator: Scott Gettinger
A Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Roy Herbst
A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction With Nab-Paclitaxel (Abraxane®) Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC)
Disease/Condition: Lung
Principal Investigator: Kert Sabbath
A Randomized Phase II Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption
Disease/Condition: Other Skin
Principal Investigator: Jennifer Choi
A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Disease/Condition: Lung
Principal Investigator: Anne Chiang
Lung Cancer Mutation Consortium Protocol
Disease/Condition: Lung
Principal Investigator: Katerina Politi
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Anne Chiang